The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection

European Respiratory Journal

Volumn 45, Issue 2, 2015, Pages 571-574

  Esposito, Susanna ^a   Codecasa, Luigi R ^b   Centis, Rosella ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b Directorate General of Health of the Lombardy Region   (Italy)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DELAMANID; LINEZOLID; RIFAMPICIN; NITROIMIDAZOLE DERIVATIVE; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; COST CONTROL; COST UTILITY ANALYSIS; DISEASE ELIMINATION; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG MONITORING; HEALTH CARE AVAILABILITY; HEALTH CARE MANAGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LETTER; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MOLECULAR DIAGNOSTICS; PERSONALIZED MEDICINE; TREATMENT OUTCOME; TUBERCULOSIS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MALE;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MALE; NITROIMIDAZOLES; OXAZOLES;

EID: 84922200165     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00157914     Document Type: Letter

References (9)

1. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014;44:811-815.
2. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42:156-168.
3. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013;42:169-179.
4. Sotgiu G, Mauch V, Migliori GB, et al. Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster. Eur Respir J 2014;43:1563-1566.
5. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013;42:785-801.
6. Voniatis C, Migliori GB, Voniatis M, et al. Tuberculosis elimination: dream or reality? The case of Cyprus. Eur Respir J 2014;44:543-546.
7. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014;43:1410-1420.
8. Zvada SP, Denti P, Donald PR, et al. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. J Antimicrob Chemother 2014;69:1339-1349.
9. Codecasa LR, Ciconali G, Mazzola E, et al. Managing an extensively drug-resistant tuberculosis outbreak: the public health face of the medal. Eur Respir J 2015;45:292-294.